SOURCE Shenzhen Chipscreen Biosciences, Ltd. View original content:http://www.prnewswire.com/news-releases/chipscreen-received-a-phase-1b2-clinical-trial-of-chiauranibcs2164-ind-clearance-from-the-us-food-and-drug-administration-fda-301270466.html
Company Codes: Shanghai:688321
About CHIPSCREEN BIOSCIENCES “With this clearance of US FDA IND application for CS2164, it will certainly increase success of our global development strategy based on early efficacy and safety data obtained from China trials,” said Dr. Xianping Lu, Chairman and President of Chipscreen.
Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen Biosciences, Stock Symbol: 688321.SH) was founded in Shenzhen in 2001, specializing in the research and development of novel small molecule drugs. Within house-built proprietary chemical genomics-based drug discovery and early evaluation platform as its core competitiveness, integrated Chipscreen Biosciences has now become one of China’s leading innovative drug enterprises, forming a modern biopharmaceutical group company in Shenzhen, as its headquarter, research and development center and GMP production base, Chengdu, as a regional headquarter, second research and development center, and a large scale GMP production base for both drug substances and products, Beijing clinical research center, Shanghai commercial center, and CHIPSCREEN BIOSCIENCES (United States) Limited. At present, the company has developed several original new drug product lines for oncology, metabolic diseases, autoimmune diseases, central nervous diseases, and antiviral diseases. The primary objective of this Phase Ib/2 study in the USA is to demonstrate safety, tolerability and efficacy of Chiauranib as a monotherapy in 24 to 36 patients with SCLC.
Source
The News Highlights
- Chipscreen received a Phase 1b / 2 clinical trial of Chiauranib / CS2164 IND release from the U.S. Food and Drug Administration (FDA)
- Check the latest Gaming news updates and information about games.
- Please share this news with your friends and family to support us your one share helps us a lot.
- Follow us on Facebook and Twitter, for similar updates.